Exelixis Research Development vs Selling General Administrative Analysis

EXEL Stock

USD 35.93 0.52 1.43%

Exelixis financial indicator trend analysis is much more than just examining Exelixis latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Exelixis is a good investment. Please check the relationship between Exelixis Research Development and its Selling General Administrative accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Exelixis. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.

Research Development vs Selling General Administrative

Research Development vs Selling General Administrative Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Exelixis Research Development account and Selling General Administrative. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Exelixis' Research Development and Selling General Administrative is 0.96. Overlapping area represents the amount of variation of Research Development that can explain the historical movement of Selling General Administrative in the same time period over historical financial statements of Exelixis, assuming nothing else is changed. The correlation between historical values of Exelixis' Research Development and Selling General Administrative is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Research Development of Exelixis are associated (or correlated) with its Selling General Administrative. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Selling General Administrative has no effect on the direction of Research Development i.e., Exelixis' Research Development and Selling General Administrative go up and down completely randomly.

Correlation Coefficient

0.96

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Research Development

Selling General Administrative

Most indicators from Exelixis' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Exelixis current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Exelixis. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.At this time, Exelixis' Selling General Administrative is quite stable compared to the past year. Tax Provision is expected to rise to about 32.5 M this year, although the value of Sales General And Administrative To Revenue will most likely fall to 0.24.

	2021	2022	2023	2024 (projected)
Gross Profit	1.4B	1.6B	1.8B	1.8B
Total Revenue	1.4B	1.6B	1.8B	1.9B

Gross Profit Total Revenue

Exelixis fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Retained Earnings	Common Stock Shares Outstanding	Other Stockholder Equity	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Net Debt	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Other Liab	Other Assets	Long Term Debt
Total Assets		0.99	0.72	0.61	0.61	-0.34	0.88	0.85	0.85	-0.68	0.95	0.75	0.95	0.86	0.94	0.94	0.96	-0.21	0.89	0.34	0.96	-0.34	-0.33	-0.03	0.95	-0.55
Total Stockholder Equity	0.99		0.78	0.61	0.62	-0.43	0.82	0.78	0.8	-0.76	0.92	0.77	0.92	0.79	0.95	0.95	0.97	-0.34	0.84	0.2	0.97	-0.39	-0.26	-0.09	0.95	-0.61
Retained Earnings	0.72	0.78		0.08	0.25	-0.56	0.63	0.46	0.64	-0.61	0.67	0.49	0.7	0.63	0.66	0.69	0.69	-0.56	0.55	-0.18	0.68	-0.6	0.34	-0.35	0.74	-0.58
Common Stock Shares Outstanding	0.61	0.61	0.08		0.78	-0.2	0.36	0.5	0.3	-0.63	0.51	0.73	0.46	0.28	0.71	0.64	0.66	-0.09	0.52	0.38	0.69	-0.03	-0.67	0.24	0.54	-0.4
Other Stockholder Equity	0.61	0.62	0.25	0.78		-0.02	0.41	0.32	0.36	-0.5	0.53	0.68	0.51	0.36	0.64	0.59	0.59	0.01	0.34	0.29	0.64	-0.15	-0.59	-0.23	0.57	-0.07
Short Long Term Debt Total	-0.34	-0.43	-0.56	-0.2	-0.02		-0.14	-0.23	-0.15	0.68	-0.24	-0.31	-0.23	-0.11	-0.42	-0.45	-0.44	0.78	-0.28	0.42	-0.42	0.79	-0.27	-0.19	-0.35	0.84
Other Current Liab	0.88	0.82	0.63	0.36	0.41	-0.14		0.91	0.87	-0.44	0.94	0.59	0.88	0.94	0.79	0.83	0.8	0.03	0.9	0.52	0.81	-0.21	-0.24	0.0	0.8	-0.36
Total Current Liabilities	0.85	0.78	0.46	0.5	0.32	-0.23	0.91		0.82	-0.46	0.88	0.57	0.83	0.86	0.77	0.81	0.79	0.01	0.95	0.59	0.79	-0.17	-0.37	0.27	0.76	-0.5
Property Plant And Equipment Net	0.85	0.8	0.64	0.3	0.36	-0.15	0.87	0.82		-0.32	0.91	0.38	0.96	0.98	0.64	0.75	0.7	0.07	0.78	0.45	0.68	-0.22	-0.16	0.09	0.86	-0.42
Net Debt	-0.68	-0.76	-0.61	-0.63	-0.5	0.68	-0.44	-0.46	-0.32		-0.55	-0.86	-0.47	-0.32	-0.82	-0.82	-0.76	0.66	-0.52	0.15	-0.82	0.4	0.07	-0.06	-0.62	0.77
Accounts Payable	0.95	0.92	0.67	0.51	0.53	-0.24	0.94	0.88	0.91	-0.55		0.63	0.94	0.93	0.86	0.89	0.89	-0.08	0.91	0.43	0.88	-0.26	-0.25	0.04	0.9	-0.49
Cash	0.75	0.77	0.49	0.73	0.68	-0.31	0.59	0.57	0.38	-0.86	0.63		0.54	0.43	0.89	0.8	0.79	-0.3	0.62	0.24	0.88	-0.22	-0.36	-0.07	0.63	-0.43
Non Current Assets Total	0.95	0.92	0.7	0.46	0.51	-0.23	0.88	0.83	0.96	-0.47	0.94	0.54		0.93	0.79	0.85	0.84	-0.06	0.84	0.39	0.82	-0.29	-0.27	-0.02	0.95	-0.46
Non Currrent Assets Other	0.86	0.79	0.63	0.28	0.36	-0.11	0.94	0.86	0.98	-0.32	0.93	0.43	0.93		0.67	0.76	0.72	0.13	0.83	0.53	0.71	-0.22	-0.18	0.08	0.82	-0.36
Cash And Short Term Investments	0.94	0.95	0.66	0.71	0.64	-0.42	0.79	0.77	0.64	-0.82	0.86	0.89	0.79	0.67		0.93	0.98	-0.33	0.85	0.25	1.0	-0.35	-0.36	-0.04	0.84	-0.57
Net Receivables	0.94	0.95	0.69	0.64	0.59	-0.45	0.83	0.81	0.75	-0.82	0.89	0.8	0.85	0.76	0.93		0.91	-0.36	0.81	0.21	0.95	-0.32	-0.28	0.03	0.92	-0.66
Short Term Investments	0.96	0.97	0.69	0.66	0.59	-0.44	0.8	0.79	0.7	-0.76	0.89	0.79	0.84	0.72	0.98	0.91		-0.33	0.89	0.24	0.98	-0.39	-0.33	-0.03	0.87	-0.6
Non Current Liabilities Total	-0.21	-0.34	-0.56	-0.09	0.01	0.78	0.03	0.01	0.07	0.66	-0.08	-0.3	-0.06	0.13	-0.33	-0.36	-0.33		-0.08	0.74	-0.33	0.46	-0.42	0.22	-0.28	0.69
Other Current Assets	0.89	0.84	0.55	0.52	0.34	-0.28	0.9	0.95	0.78	-0.52	0.91	0.62	0.84	0.83	0.85	0.81	0.89	-0.08		0.5	0.86	-0.23	-0.32	0.17	0.79	-0.52
Total Liab	0.34	0.2	-0.18	0.38	0.29	0.42	0.52	0.59	0.45	0.15	0.43	0.24	0.39	0.53	0.25	0.21	0.24	0.74	0.5		0.25	0.22	-0.57	0.33	0.19	0.2
Total Current Assets	0.96	0.97	0.68	0.69	0.64	-0.42	0.81	0.79	0.68	-0.82	0.88	0.88	0.82	0.71	1.0	0.95	0.98	-0.33	0.86	0.25		-0.35	-0.34	-0.03	0.87	-0.59
Short Term Debt	-0.34	-0.39	-0.6	-0.03	-0.15	0.79	-0.21	-0.17	-0.22	0.4	-0.26	-0.22	-0.29	-0.22	-0.35	-0.32	-0.39	0.46	-0.23	0.22	-0.35		-0.16	0.13	-0.33	0.43
Common Stock	-0.33	-0.26	0.34	-0.67	-0.59	-0.27	-0.24	-0.37	-0.16	0.07	-0.25	-0.36	-0.27	-0.18	-0.36	-0.28	-0.33	-0.42	-0.32	-0.57	-0.34	-0.16		-0.16	-0.25	-0.19
Other Liab	-0.03	-0.09	-0.35	0.24	-0.23	-0.19	0.0	0.27	0.09	-0.06	0.04	-0.07	-0.02	0.08	-0.04	0.03	-0.03	0.22	0.17	0.33	-0.03	0.13	-0.16		-0.1	-0.4
Other Assets	0.95	0.95	0.74	0.54	0.57	-0.35	0.8	0.76	0.86	-0.62	0.9	0.63	0.95	0.82	0.84	0.92	0.87	-0.28	0.79	0.19	0.87	-0.33	-0.25	-0.1		-0.55
Long Term Debt	-0.55	-0.61	-0.58	-0.4	-0.07	0.84	-0.36	-0.5	-0.42	0.77	-0.49	-0.43	-0.46	-0.36	-0.57	-0.66	-0.6	0.69	-0.52	0.2	-0.59	0.43	-0.19	-0.4	-0.55

Click cells to compare fundamentals

Exelixis Account Relationship Matchups

Exelixis fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.9B	2.1B	2.6B	3.1B	2.9B	3.1B
Total Stockholder Equity	1.7B	1.9B	2.2B	2.5B	2.3B	2.4B
Retained Earnings	(559.4M)	(447.6M)	(216.5M)	(34.2M)	(173.4M)	(182.0M)
Common Stock Shares Outstanding	315.0M	318.0M	322.4M	324.6M	321.5M	178.5M
Liabilities And Stockholders Equity	1.9B	2.1B	2.6B	3.1B	2.9B	3.1B
Other Stockholder Equity	2.2B	2.3B	2.4B	2.5B	2.4B	1.4B
Short Long Term Debt Total	50.7M	49.1M	51.3M	190.2M	189.9M	179.6M
Other Current Liab	21.7M	179.2M	313.3M	284.2M	360.5M	378.5M
Total Current Liabilities	142.7M	204.7M	337.6M	324.4M	394.3M	414.0M
Property Plant And Equipment Net	90.7M	67.4M	104.0M	401.2M	470.9M	494.4M
Net Debt	(215.8M)	(270.1M)	(595.9M)	(311.0M)	(73.1M)	(69.4M)
Accounts Payable	11.6M	23.6M	24.3M	32.7M	33.8M	35.5M
Cash	266.5M	319.2M	647.2M	501.2M	263.0M	190.9M
Non Current Assets Total	874.5M	691.9M	781.5M	1.5B	1.6B	1.7B
Non Currrent Assets Other	11.3M	71.9M	131.0M	290.6M	334.2M	350.9M
Cash And Short Term Investments	852.2M	1.2B	1.5B	1.3B	995.3M	1.0B
Net Receivables	119.1M	160.9M	282.7M	214.8M	237.4M	249.3M
Short Term Investments	585.7M	887.3M	819.9M	807.3M	732.3M	768.9M
Non Current Liabilities Total	57.0M	53.6M	68.0M	258.7M	284.2M	213.1M
Other Current Assets	27.0M	57.0M	57.5M	62.2M	67.9M	71.3M
Total Liab	199.7M	258.2M	405.6M	583.1M	678.4M	370.3M
Total Current Assets	1.0B	1.4B	1.8B	1.6B	1.3B	1.4B
Accumulated Other Comprehensive Income	3.1M	4.5M	(758K)	(14.5M)	(3.8M)	(3.9M)
Short Term Debt	2.7M	3.0M	8.7M	17.7M	25.7M	50.4M
Common Stock	305K	312K	319K	324K	303K	287.9K
Other Liab	8.9M	4.5M	16.8M	68.5M	78.8M	83.4M
Other Assets	185.3M	187.1M	197.5M	286.9M	329.9M	346.4M
Common Stock Total Equity	300K	305K	312K	324K	372.6K	391.2K
Inventory	12.9M	21.0M	27.5M	33.3M	17.3M	9.5M
Property Plant And Equipment Gross	90.7M	67.4M	144.9M	462.1M	551.2M	578.8M
Property Plant Equipment	48.9M	67.4M	149.2M	110.6M	127.2M	133.6M
Current Deferred Revenue	106.7M	1.8M	8.7M	6.6M	5.4M	5.1M
Net Tangible Assets	1.6B	1.8B	2.0B	2.4B	2.8B	2.9B
Retained Earnings Total Equity	(880.4M)	(559.4M)	(447.6M)	(34.2M)	(39.4M)	(41.3M)
Capital Surpluse	2.2B	2.2B	2.3B	2.5B	2.9B	2.1B

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Exelixis is a strong investment it is important to analyze Exelixis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Exelixis' future performance. For an informed investment choice regarding Exelixis Stock, refer to the following important reports:

How To Invest In Exelixis

Details

Is Exelixis Stock a good investment?

Details

What is Exelixis' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Exelixis. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.

You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exelixis. If investors know Exelixis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exelixis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

121.699

Earnings Share

1.55

Revenue Per Share

7.032

Quarterly Revenue Growth

0.143

Return On Assets

0.1281

The market value of Exelixis is measured differently than its book value, which is the value of Exelixis that is recorded on the company's balance sheet. Investors also form their own opinion of Exelixis' value that differs from its market value or its book value, called intrinsic value, which is Exelixis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exelixis' market value can be influenced by many factors that don't directly affect Exelixis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Exelixis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Exelixis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exelixis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Exelixis Research Development vs Selling General Administrative Analysis

Research Development vs Selling General Administrative

Research Development vs Selling General Administrative Correlation Analysis

Correlation Coefficient

Research Development

Selling General Administrative

Exelixis fundamental ratios Correlations

Exelixis Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Exelixis fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Stockholder Equity	+ 0.99	Total Assets
Non Currrent Assets Other	+ 0.98	Property Plant And Equipment Net
Short Term Investments	+ 0.98	Cash And Short Term Investments
Total Current Assets	+ 0.98	Short Term Investments
Short Term Investments	+ 0.97	Total Stockholder Equity

Cash	- 0.86	Net Debt
Total Current Assets	- 0.82	Net Debt
Net Receivables	- 0.82	Net Debt
Cash And Short Term Investments	- 0.82	Net Debt
Short Term Investments	- 0.76	Net Debt
Net Debt	- 0.76	Total Stockholder Equity